Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02733185 · ClinicalTrials.gov registry record · Phase 3
Trial to Assess Chelation Therapy 2
A Phase 3 study, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT02733185: Completed Phase 3 study, sponsored by Mt. Sinai Medical Center, Miami.
NCT02733185 is a Phase 3 study that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 1,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02733185, a Phase 3 study, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction (MI).
Primary Outcome
Time to first event: myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or death from any cause
Interventions
- DRUG disodium EDTA
- DIETARY_SUPPLEMENT Oral Multi Vitamins/Minerals (OMVM)
- DRUG Placebo disodium EDTA
- DIETARY_SUPPLEMENT Placebo Oral Multi Vitamins/Minerals (OMVM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2016-10-01 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
What the finished NCT02733185 record still lists
NCT02733185 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 4 interventions - of which disodium EDTA is the first listed.
NCT02733185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02733185 about?
NCT02733185 is a clinical study titled "Trial to Assess Chelation Therapy 2". Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction (MI).
What is the current status of trial NCT02733185?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2016-10-01. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT02733185?
The interventions under investigation include: disodium EDTA (DRUG), Oral Multi Vitamins/Minerals (OMVM) (DIETARY_SUPPLEMENT), Placebo disodium EDTA (DRUG), Placebo Oral Multi Vitamins/Minerals (OMVM) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02733185?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02733185's enrollment target sits among peer trials
1,000 296th of 2000 higher than 1,689 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI